Patent Issued for Immunogenic composition (USPTO 12076352).

Glaxosmithkline Biologicals SA has been granted a patent for an immunogenic composition involving engineered bacteriophages. These viruses are designed to target commensal bacteria and insert antigens into them, triggering an immune response without harming the bacteria. The technology has potential applications in treating bacterial infections and cancer therapy. The article also mentions various topics related to biotechnology and pharmaceutical companies, including virions, lysogeny, oncology, viral RNA, nanomedicines, bioengineering, and genetic processes. GlaxoSmithKline Biologicals SA is likely involved in these research areas. [Extracted from the article]